← back to search

Yunlong Cao

Pioneer (United States) · CN
Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Animal Virus Infections Studies, and SARS-CoV-2 detection and testing.
h-index
36
citations
11,352
works
141
NIH funding
primary concept
Biology
email

Recent publications

Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V <sub>H</sub> 1-2-rearranging mouse models
Proceedings of the National Academy of Sciences 2026cited by 2position: middledoi
Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V&lt;sub&gt;H&lt;/sub&gt;1-2-rearranging mouse models.
2026cited by 0position: contributordoi
Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV.
2026cited by 0position: contributordoi
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
2025cited by 124position: contributordoi
Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.
2025cited by 25position: contributordoi
Deciphering SARS-CoV-2 evolution under antibody immune pressure.
2025cited by 1position: contributordoi
SARS-CoV-2 keeps evolving, so must our research efforts.
2025cited by 1position: contributordoi
Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants.
2025cited by 0position: contributordoi
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.
2024cited by 233position: contributordoi
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages
Proceedings of the National Academy of Sciences 2024cited by 38position: middledoi
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages.
2024cited by 30position: contributordoi
Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2.
2024cited by 26position: contributordoi
Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic.
2024cited by 5position: contributordoi
The delivery device of SARS-CoV-2 mucosal vaccine matters.
2024cited by 1position: contributordoi
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.
2023cited by 761position: contributordoi
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure
The Lancet Infectious Diseases 2023cited by 391position: lastdoi
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
2023cited by 262position: contributordoi
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting
Nature 2023cited by 259position: lastdoi
Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding.
2023cited by 114position: contributordoi
Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution.
2023cited by 58position: contributordoi
Single-cell bisulfite-free 5mC and 5hmC sequencing with high sensitivity and scalability.
2023cited by 34position: contributordoi
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.
2023cited by 5position: contributordoi
Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study
2023cited by 0position: contributordoi
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
2022cited by 1,688position: contributordoi
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
2022cited by 1,167position: contributordoi
Circular RNA vaccines against SARS-CoV-2 and emerging variants
Cell 2022cited by 598position: middledoi
Circular RNA vaccines against SARS-CoV-2 and emerging variants.
2022cited by 443position: contributordoi
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cell 2022cited by 422position: contributordoi
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
2022cited by 163position: contributordoi
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.
2022cited by 146position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 18 papers (2021–2026)Junyu Xiao · King University14 papers (2020–2024) · 14 papers (2020–2024)Jing Wang · King University13 papers (2021–2025)Xiaoliang Sunney Xie · Fuzhou University12 papers (2021–2024)Youchun Wang · Beijing Advanced Sciences and Innovation Center11 papers (2021–2025) · 10 papers (2021–2026) · 10 papers (2021–2024)Weijin Huang · Institute for Biological Product Control10 papers (2020–2022) · 10 papers (2021–2025)Xiangxi Wang · Chinese Academy of Sciences8 papers (2021–2026) · 8 papers (2021–2026)Qianqian Li · First Hospital of Lanzhou University6 papers (2021–2022) · 6 papers (2022–2025) · 5 papers (2021–2022) · 5 papers (2021–2022) · 5 papers (2024–2025)Yingmei Feng · Huazhong University of Science and Technology4 papers (2020–2022) · 4 papers (2022–2025) · 4 papers (2020–2025)